{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:53Z","timestamp":1794978653959,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific antibodies (BsAbs) are effective treatments in aggressive B-cell lymphomas but carry immune-mediated risks of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS), particularly during the first cycle. We analyzed 255 patients receiving BsAbs across 14 institutions to identify predictors of CRS\/ICANS. CRS occurred in 31% (grade \u2265 3 in 5%) and ICANS in 8% (grade \u2265 3 in 2%) of patients, with no significant differences across glofitamab, mosunetuzumab, or epcoritamab. CRS rates with glofitamab and epcoritamab as monotherapy were lower than reported in trials. In multivariable analysis, concurrent systemic chemotherapy was associated with grade \u22652 CRS, and the development of any-grade CRS and elevated ferritin independently was associated with ICANS. In those with available data, all patients with grade \u22653 CRS had very high serum C-reactive protein (\u226515 mg\/L) and elevated ferritin (&amp;gt;336 ng\/mL). These findings identify candidate laboratory thresholds and treatment-related factors that warrant prospection validation for risk stratification and outpatient BsAb administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020595","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:22:41Z","timestamp":1790259761000},"page":"7788-7796","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for CRS and ICANS with bispecific antibodies for aggressive lymphomas"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7431-3771","authenticated-orcid":false,"given":"Victoria","family":"Gill","sequence":"first","affiliation":[{"name":"1The Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas","family":"Ollila","sequence":"additional","affiliation":[{"name":"2Brown University Health Cancer Institute, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6161-1459","authenticated-orcid":false,"given":"Urmi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"1The Warren Alpert Medical School of Brown University, Providence, RI"},{"name":"3Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"},{"name":"5The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9188-5008","authenticated-orcid":false,"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"6Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.","family":"Thomas","sequence":"additional","affiliation":[{"name":"7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun K.","family":"Tiger","sequence":"additional","affiliation":[{"name":"8Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-537X","authenticated-orcid":false,"given":"Alexandra","family":"Noveihed","sequence":"additional","affiliation":[{"name":"8Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cortese","sequence":"additional","affiliation":[{"name":"9Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"9Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"10Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hess","sequence":"additional","affiliation":[{"name":"10Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3961-4235","authenticated-orcid":false,"given":"Adam","family":"Kidwell","sequence":"additional","affiliation":[{"name":"11Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"11Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara K.","family":"Moyo","sequence":"additional","affiliation":[{"name":"12Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Altomare","sequence":"additional","affiliation":[{"name":"13Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"14Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-1410","authenticated-orcid":false,"given":"Megan","family":"Melody","sequence":"additional","affiliation":[{"name":"15Tampa General Hospital Cancer Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Dharia","sequence":"additional","affiliation":[{"name":"16University of South Florida Health Morsani College of Medicine, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee","family":"Kenkre","sequence":"additional","affiliation":[{"name":"17Carbone Cancer Center, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[{"name":"18City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9749-7599","authenticated-orcid":false,"given":"Jonathan","family":"Moreira","sequence":"additional","affiliation":[{"name":"19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-3305","authenticated-orcid":false,"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-7064","authenticated-orcid":false,"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"2Brown University Health Cancer Institute, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2026111611263046000_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"2026111611263046000_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026111611263046000_bib3","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026111611263046000_bib4","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1182\/blood-2022-171084","article-title":"Baseline CRP and ferritin identify patients at high risk of poor outcomes after axicabtagene ciloleucel despite corticosteroid prophylaxis","volume":"140","author":"Faramand","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026111611263046000_bib5","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"2026111611263046000_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl 16","key":"2026111611263046000_bib7","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/JCO.2024.42.16_suppl.7036","article-title":"Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell\u2013associated neurotoxicity syndrome (ICANS)","volume":"42","author":"George","year":"2024","journal-title":"JCO"},{"issue":"10","key":"2026111611263046000_bib8","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"2026111611263046000_bib9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10466","key":"2026111611263046000_bib10","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"2026111611263046000_bib11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026111611263046000_bib12","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026111611263046000_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026111611263046000_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"2026111611263046000_bib15","doi-asserted-by":"crossref","first-page":"e250048","DOI":"10.6004\/jnccn.2025.0048","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas 3.2025: featured updates to the NCCN guidelines","volume":"23","author":"Zelenetz","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"36","key":"2026111611263046000_bib16","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"JCO"},{"issue":"1","key":"2026111611263046000_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026111611263046000_bib18","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.3390\/cancers13215287","article-title":"Risk, characteristics and biomarkers of cytokine release syndrome in patients with relapsed\/refractory AML or MDS treated with CD3xCD123 bispecific antibody APVO436","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2026111611263046000_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2025-401","article-title":"Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: a multi-center, retrospective, real world analysis","volume":"146","author":"Yang","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026111611263046000_bib20","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/blood-2023-181985","article-title":"Significant cytokine release syndrome risk model with T-cell engaging therapies","volume":"142","author":"Lafeuille","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2026111611263046000_bib21","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026111611263046000_bib22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3324\/haematol.2024.285343","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"2026111611263046000_bib23","unstructured":"American Board of Internal Medicine\n          . ABIM Laboratory Test Reference Ranges\u2013January 2025. Accessed 1 August 2025. https:\/\/www.abim.org\/media\/e2wdwdqu\/laboratory-reference-ranges.pdf."},{"key":"2026111611263046000_bib24","unstructured":"R Core Team\n          . R: A Language and Environment for Statistical Computing. Accessed 29 September 2026. https:\/\/www.R-project.org\/."},{"issue":"10","key":"2026111611263046000_bib25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transpl"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7788\/2600710\/blooda_adv-2026-020595-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7788\/2600710\/blooda_adv-2026-020595-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:26:42Z","timestamp":1794846402000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7788\/571169\/Risk-factors-for-CRS-and-ICANS-with-bispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020595","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}